Clinical trial • Phase III • Oncology|Neurology

melflufen for Recurrent glioblastoma|Glioblastoma

Phase III trial of melflufen for Recurrent glioblastoma|Glioblastoma. 10 participants.

Overview

Trial Therapeutic Area
Oncology|Neurology
Trial Disease
Recurrent glioblastoma|Glioblastoma
Trial Stage
Phase III

Key dates

Initial CTIS Submission Date
13-03-2026
First CTIS Authorization Date
15-05-2026

Trial design

Phase III trial across 1 site in Norway.

Target Sample Size
10

Eligibility

Recruits 10 Vulnerable population not selected; no specific consent or assent handling described in the record..

Vulnerable Population
Vulnerable population not selected; no specific consent or assent handling described in the record.

Recruitment

Planned Sample Size
10
Recruitment Window Months
13

Geography

Total Number Of Sites
1
Total Number Of Participants
10

Norway

Earliest CTIS Part Ii Submission Date
11-05-2026
Latest Decision Or Authorization Date
15-05-2026
Processing Time Days
4
Number Of Sites
1
Number Of Participants
10

Sites

Site Name
Oslo Universitetssykehus HF
Department Name
Department of Oncology
Contact Person Name
Petter Brandal
Contact Person Email
pebra@ous-hf.no
Number Of Participants
10

Sponsor

Primary sponsor

Full Name
Oncopeptides AB
Organisation Type
Pharmaceutical company
Country Of Registered Address
Sweden

Investigational products

Investigational Product Name
melflufen
Active Substance
melflufen

Related trials

Other published trials that may interest you.